A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational Study
Notable advancements in the drug development market were witnessed between 2015 and 2022, and 2023 was no different. The total number of novel drugs approved was significantly higher than the previous year. Expedited approval of anticancer drugs and biologics is seen as a recent trend in drug development.
Authors
- Ajay Kumar Shukla (ORCID: https://orcid.org/0000-0002-1164-6056)
- Saurav Misra (ORCID: https://orcid.org/0000-0003-2011-5895)
Institutions
- All India Institute of Medical Sciences Bhopal (IN)
- Kalpana Chawla Government Medical College and Hospital (IN)
Publication Details
- Journal
- Journal of Pharmacy And Bioallied Sciences
- Published
- 2025-01-01
- DOI
- https://doi.org/10.4103/jpbs.jpbs_730_25
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00